欢迎访问《中国实验方剂学杂志》编辑部网站!
脉络学说营卫理论指导血管病变防治研究
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家重点基础研究发展计划(973计划)项目(2005CB523301,2012CB518606)


Research on Guidance of Prevention and Treatment of Vascular Diseases by Yingwei Theory of Vessel-collateral Theory
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    继承发展血脉理论,结合中医气血相关理论特色,汲取主持承担的2项国家973计划项目研究成果,系统构建指导血管病变防治的脉络学说,把中医络病学学科的学术发展从"络病证治"推向"脉络学说"研究的历史新阶段。系统研究脉络病变发病规律、基本病机、临床证候及辨证治疗,提出脉络学说核心内容——营卫理论,建立"脉络-血管系统病"辨证诊断标准,完善发展了中医血脉理论。深化发展脉络学说营卫理论,提出营卫交感和营卫"由络以通、交会生化"理论指导血管病变防治研究,以"孙络-微血管"为研究切入点,提出四类微观病理特征,证实通络保护"孙络-微血管"是治疗心、脑和(糖)肾重大疾病共性关键机制——保护微血管、改善血流灌注、保护组织细胞、改善脏器功能,通络保护微血管内皮细胞是治疗"孙络-微血管"病变核心机制,提出保护微血管内皮细胞是解决微血管病变难题的新策略。历经十余年,完成4项循证医学研究解决急性心梗无再流临床难题,为心功能不全伴室性早搏国际医学界难题提供新药物,填补窦缓伴早搏快慢兼治、整合调律的药物治疗空白,明显提高慢性心力衰竭临床治疗效果,取得中医药治疗微血管病变重大突破,受到国内外医学界的充分认可和高度评价,推动了脉络学说营卫理论指导下的专科平台建设和学科学会发展,以及脉络病变辨证诊疗方法和药物的临床应用,具有显著的社会效益和经济效益。

    Abstract:

    The blood-vein theory is inherited and developed. Combined with the related theory features of Qi and blood of traditional Chinese medicine(TCM), the progress results in two national 973 plan projects undertaken are learned from, the vessel-collateral theory guiding the prevention and treatment of vascular lesions is systematically built, the academic development of TCM collateral disease discipline is pushed from "treatment of symptoms of collateral disease" to study on "vessel-collateral theory", a new stage in the history. The pathogenesis, basic pathogenesis, clinical syndrome and syndrome differentiation therapy of vessel-collateral lesions are systematically studied, Yingwei theory, the core content of vessel-collateral theory, is proposed, the syndrome differential diagnosis standard of "vessel-collateral-vascular system disease" is established, and the blood-vessel theory of TCM is improved. The development of Yingwei theory of vessel-collateral theory is deepened. The theory of Yingwei sympathia and Yingwei's "opening by collaterals, intersecting and generating" are proposed to guide the study on prevention and control of vascular lesions. With tertiary collaterals-microvessel as a breakthrough point of research, four types of microscopic pathological features of microvessels are proposed. It is confirmed that dredging collaterals and protecting tertiary collaterals-microvessel is the common key mechanism for the treatment of major diseases of heart, brain and kidney(sugar). It protects microvessels, improves blood flow perfusion, protects tissue cells, and improves the viscera function. Dredging collaterals and protecting microvascular endothelial cells is the core mechanism of treating tertiary collaterals-microvessel lesions. It is proposed that protection of microvascular endothelial cells is a new strategy to solve the problem of microvascular lesions. After more than ten years, four studies of evidence-based medicine have been completed to solve the clinical problem of acute myocardial infarction without reflow. New drugs are provided to the international medical problem of cardiac insufficiency with premature ventricular contraction. The gap of fast and slow treatment, integration and rhythm adjustment of sinus bradycardia with premature ventricular contraction is filled. The clinical treatment effect of chronic heart failure is significantly improved, a major breakthrough in the treatment of microvascular lesions by TCM is achieved, and it is fully recognized and highly evaluated by the medical profession at home and abroad. It promotes the specialized subject platform construction and society development under the guidance of Yingwei theory of vessel-collateral theory, as well as the clinical application of syndrome differentiation diagnosis and treatment method and drugs of vessel-collateral lesions, and has significant social and economic benefits.

    参考文献
    相似文献
    引证文献
引用本文

吴以岭,贾振华,常丽萍,魏聪.脉络学说营卫理论指导血管病变防治研究[J].中国实验方剂学杂志,2019,25():1~10

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-12-28
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2019-01-10
  • 出版日期:

地址:北京东直门内南小街16号

邮编:100700

电话:010-84076882

E-mail:syfjx_2010@188.com

中国实验方剂学杂志 ® 2021 版权所有

技术支持:北京勤云科技发展有限公司